Survodutide (BI 456906)
Dual GLP-1/Glucagon Receptor Agonist · Weight Loss & Diabetes
Overview
Investigational dual receptor agonist targeting metabolic disease through balanced GLP-1R and GCGR activation. Phase 2/3 clinical trials demonstrate superior weight loss and MASH treatment efficacy.
Dual agonism: GLP-1R reduces appetite and slows gastric emptying; GCGR increases energy expenditure and hepatic fat oxidation. EC50 0.52nM GCGR, 0.33nM GLP-1R.
14.9% mean weight loss at 46 weeks (4.8mg); 55% achieved ≥15% reduction.
Superior to semaglutide: -8.7% vs -5.3% at 16 weeks.
Dual mechanism addresses both energy intake and expenditure.
62% achieved MASH improvement without fibrosis worsening at 4.8mg.
Mechanism
Investigational dual receptor agonist targeting metabolic disease through balanced GLP-1R and GCGR activation. Phase 2/3 clinical trials demonstrate superior weight loss and MASH treatment efficacy.
Dual agonism: GLP-1R reduces appetite and slows gastric emptying; GCGR increases energy expenditure and hepatic fat oxidation. EC50 0.52nM GCGR, 0.33nM GLP-1R.
14.9% mean weight loss at 46 weeks (4.8mg); 55% achieved ≥15% reduction.
Research areas
- Investigational dual receptor agonist targeting metabolic disease through balanced GLP-1R and GCGR activation. Phase 2/3 clinical trials demonstrate superior weight loss and MASH treatment efficacy.
- Dual agonism: GLP-1R reduces appetite and slows gastric emptying; GCGR increases energy expenditure and hepatic fat oxidation. EC50 0.52nM GCGR, 0.33nM GLP-1R.
- 14.9% mean weight loss at 46 weeks (4.8mg); 55% achieved ≥15% reduction.
- Superior to semaglutide: -8.7% vs -5.3% at 16 weeks.
- Dual mechanism addresses both energy intake and expenditure.
- 62% achieved MASH improvement without fibrosis worsening at 4.8mg.
- 63-67% achieved ≥30% liver fat reduction.
- HbA1c reduction up to -1.6% at highest doses.
Research notes
- Nausea (40-66%)
- Diarrhea (25-49%)
- Vomiting (15-41%)
- Slight heart rate increase (mean 2-5 bpm)
- Severe persistent nausea/vomiting preventing oral intake
- Signs of pancreatitis (severe abdominal pain radiating to back)
- Allergic reactions (rash, itching, difficulty breathing)
- Severe hypoglycemia with insulin/sulfonylureas
- Gallbladder symptoms (right upper quadrant pain)
- Significant tachycardia or arrhythmias
- Not recommended in pregnancy or breastfeeding
- Use contraception during treatment
Pharmacokinetics
- Yes, the ~6-day half-life allows effective once-weekly dosing because peak levels remain therapeutic throughout the week. This contrasts with semaglutide (7-day half-life) - survodutide's slightly shorter half-life still covers the weekly interval adequately.
FAQs
Why is survodutide superior to semaglutide for weight loss?
Survodutide adds glucagon receptor agonism to GLP-1 effects, creating dual appetite suppression and energy expenditure increase. Head-to-head trials show -8.7% weight loss vs semaglutide's -5.3% at 16 weeks, because the glucagon pathway enhances fat burning independent of appetite.
Can survodutide reverse MASH (metabolic dysfunction-associated steatohepatitis)?
Yes, clinical trials show 62% of MASH patients achieved improvement without fibrosis worsening at 4.8mg weekly, with 63-67% achieving ≥30% liver fat reduction. This makes it one of the first investigational agents with FDA potential for both MASH treatment and weight loss.
Does survodutide cause heart rate increases like other GLP-1 drugs?
Survodutide shows a mean 2-5 bpm heart rate increase, similar to semaglutide. The glucagon receptor activation is modest enough to avoid significant tachycardia, though patients with cardiac conditions should monitor closely as with all GLP-1 agonists.